EL
Eledon Pharmaceuticals, Inc.
ELDN · NASDAQ
$2.78 +0.00% (+$0.00)
1M -26.26%
Market Cap $214.6M
P/E Ratio -
Div. Yield -
ROE 136.45%
Bulios Fair Price
$1.92
30.9% downside
Current Price
$2.78
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ELDN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
67 /100
Cheap P/B 2.98x
P/FCF N/A
P/S N/A
Growth
19 /100
Declining Book val. growth 1.24%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROA 78.16%
ROIC 73.80%
Debt
100 /100
Low Current ratio 7.90x
Debt/Equity 0.01x
Net debt/EBITDA N/A
Stability
60 /100
Moderate EPS volatility 34.58%
Profitable years 0
Beta 0.96x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ELDN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David-Alexandre C. Gros
Employees
33
Headquarters
Irvine
Upcoming events
13 NOV
Earnings
Upcoming earnings report